Drug Profile
Research programme: chemokine-toxin fusion proteins - CoMentis
Alternative Names: Leukocyte Population Modulators; OPL-CCL11-LPM; OPL-CXCL12-LPMLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Osprey Pharmaceuticals
- Developer CoMentis
- Class Chemokines; Proteins
- Mechanism of Action CCR2 receptor antagonists; CCR3 receptor antagonists; Chemokine CXCL12 inhibitors; CXCR4 receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic asthma; Cancer; CNS disorders; Gastroenteritis; Nephritis; Pulmonary eosinophilia; Rheumatoid arthritis; Skin disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-asthma in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in Canada